Compare StemCell Institute with Similar Stocks
Dashboard
1
With a fall in Net Sales of -8.45%, the company declared Very Negative results in Mar 26
- The company has declared negative results for the last 5 consecutive quarters
- ROCE(HY) Lowest at 5.8%
- DEBTORS TURNOVER RATIO(HY) Lowest at 1.35 times
- INTEREST COVERAGE RATIO(Q) Lowest at 1,968.37
2
With ROE of 7.15%, it has a very expensive valuation with a 3.21 Price to Book Value
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 6,937 Million (Micro Cap)
45.00
NA
0.00%
-0.97
7.15%
2.61
Revenue and Profits:
Net Sales:
667 Million
(Quarterly Results - Mar 2026)
Net Profit:
-14 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.51%
0%
-16.51%
6 Months
-9.06%
0%
-9.06%
1 Year
-30.12%
0%
-30.12%
2 Years
-57.55%
0%
-57.55%
3 Years
-75.88%
0%
-75.88%
4 Years
-82.45%
0%
-82.45%
5 Years
-65.96%
0%
-65.96%
StemCell Institute for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.76%
EBIT Growth (5y)
14.05%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.91
Tax Ratio
31.80%
Dividend Payout Ratio
66.37%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
10.52%
Valuation key factors
Factor
Value
P/E Ratio
45
Industry P/E
Price to Book Value
3.21
EV to EBIT
21.50
EV to EBITDA
14.07
EV to Capital Employed
70.00
EV to Sales
2.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
325.66%
ROE (Latest)
7.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
667.30
728.90
-8.45%
Operating Profit (PBDIT) excl Other Income
29.70
127.50
-76.71%
Interest
1.50
1.30
15.38%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-13.50
59.60
-122.65%
Operating Profit Margin (Excl OI)
-23.70%
120.90%
-14.46%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -8.45% vs 2.07% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -122.65% vs 42.58% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
2,811.30
2,679.20
4.93%
Operating Profit (PBDIT) excl Other Income
359.40
546.30
-34.21%
Interest
5.40
1.20
350.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
131.00
385.80
-66.04%
Operating Profit Margin (Excl OI)
72.10%
156.20%
-8.41%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 4.93% vs 7.98% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -66.04% vs 24.05% in Mar 2025
About StemCell Institute 
StemCell Institute
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






